Ulcerative Colitis Treatment Patterns and Cost of Care Kyle D. Null, PhD, Yihua Xu, PhD, Margaret K. Pasquale, PhD, Chinyu Su, MD, Amy Marren, MD, James Harnett, PharmD, Jack Mardekian, PhD, Alireza Manuchehri, MD, Paul Healey, MD  Value in Health  Volume 20, Issue 6, Pages 752-761 (June 2017) DOI: 10.1016/j.jval.2017.02.005 Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Attrition flow for study cohort identification, inclusion, and exclusion. ADA, adalimumab; IFX, infliximab; UC, ulcerative colitis. *The 6-mo pre- and postindex was used to capture UC diagnosis to account for possible claims lag or a delay in a “definitive” UC diagnosis. **Continuous enrollment ensured that patients were consistently enrolled in a Humana plan during minimum required pre- and postindex periods. Evidence of a paid claim for ADA or IFX must have been in the period July 1, 2007, to December 31, 2013. Value in Health 2017 20, 752-761DOI: (10.1016/j.jval.2017.02.005) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. S1 Proportion of treatment group membership per quarter over 36 months post-index. Value in Health 2017 20, 752-761DOI: (10.1016/j.jval.2017.02.005) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions